


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



四环医药
SihuanPharm

Sihuan Pharmaceutical Holdings Group Ltd.

四環醫藥控股集團有限公司

(incorporated in Bermuda with limited liability)

(Stock Code: 0460)

VOLUNTARY ANNOUNCEMENT

DOPAMINE HYDROCHLORIDE INJECTION

OBTAINED DRUG REGISTRATION APPROVAL FROM NMPA

The board of directors (the “**Board**”) of Sihuan Pharmaceutical Holdings Group Ltd. (the “**Company**” or “**Sihuan Pharmaceutical**”, together with its subsidiaries, the “**Group**”) is pleased to announce that Dopamine Hydrochloride Injection (strength: 2.5ml: 50mg; 5ml: 100mg) developed by the Group’s subsidiary Jilin Zhen'ao Pharmaceutical Co., Ltd. (“**Jilin Zhen'ao**”), for the treatment of shock, has obtained the drug registration approval from the National Medical Products Administration (the “**NMPA**”) of the People’s Republic of China (“**China**”). It is deemed to have passed the consistency evaluation on quality and efficacy of generic drugs.

About Dopamine Hydrochloride Injection

Dopamine Hydrochloride is a positive inotropic drug that causes an increase in heart rate and cardiac systolic force, as well as an increase in peripheral vascular systolic and diastolic pressures by stimulating adrenergic receptors and increasing the release of norepinephrine. Dopamine Hydrochloride Injection is indicated for shock syndromes caused by myocardial infarction, trauma, endotoxic sepsis, cardiac surgery, renal failure, congestive heart failure, etc.; shock that is not corrected by volume replacement, especially in cases of oliguria and normal or low peripheral vascular resistance. Since this product can increase cardiac output, it is also used in cardiac insufficiency where digitalis and diuretics are ineffective.

Dopamine hydrochloride injection is a Category A drug under the National Reimbursement Drug List (NRDL), and a National essential drug. Dopamine hydrochloride injection (strength: 2.5ml: 50mg; 5ml: 100mg) has been approved for drug registration, which will further benefit a wide range of patients. It also adds another important product to the Group's cardiovascular drug pipeline, which will facilitate future sales and market competition for this product and have a positive impact on the Group's operating results.

About Sihuan Pharmaceutical

Founded in 2001 and listed on the Main Board of The Stock Exchange of Hong Kong Limited in 2010, Sihuan Pharmaceutical is an international medical aesthetic and pharmaceutical company led by innovation, with an independent and leading research and development technology platform, a rich global product pipeline, strong product registration capability, a full dosage form production platform with high efficiency and low cost and a mature and excellent sales system. Adhering to the overall strategic goal for the "full promotion of a two-wheel drive strategy of its medical aesthetics and biopharmaceutical businesses", Sihuan Pharmaceutical endeavors to build itself into a leading medical aesthetics and biopharmaceutical company in China.

This announcement is being made by the Company on a voluntary basis to update the investing public on the Group's latest business development, and does not constitute, and is not intended to be, an advertisement regarding the use of any medicine, surgical appliance, treatment or orally consumed product.

By order of the Board
Sihuan Pharmaceutical Holdings Group Ltd.
Dr. Che Fengsheng
Chairman and Executive Director

Hong Kong, 6 July 2023

As at the date of this announcement, the executive directors of the Company are Dr. Che Fengsheng (Chairman), Dr. Guo Weicheng (Deputy Chairman and Chief Executive Officer), Dr. Zhang Jionglong, Ms. Chen Yanling and Ms. Miao Guili; and the independent non-executive directors of the Company are Mr. Tsang Wah Kwong, Dr. Zhu Xun and Mr. Wang Guan.